Cracking the CRS Code in Myeloma: Insights from a Comprehensive Case Review
Host: Caitlin Costello, MD
\n\n Guest: Sagar Lonial, MD, FACP
\n\n\n \n
Bispecific antibodies are the newest immunotherapies approved for heavily pretreated relapsed/refractory myeloma, and they are shown to double response rates. Are you ready to use them in your practice? Join Drs. Costello and Lonial as they explore a case study that demonstrates how to select patients, prepare them for treatment, and effectively manage treatment-related side effects.